
|Videos|March 29, 2021
Examining the Role of Frontline BTKi Monotherapy in CLL
Author(s)Jennifer R. Brown, MD, PhD
Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5






































